Jill M. Broadfoot's most recent trade in Atyr Pharma Inc was a trade of 412,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 412,500 | 412,500 | - | - | Employee Stock Option (right to buy) | |
| Cue Biopharma Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Talphera Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2025 | 25,600 | 25,600 | - | - | Stock Option (Right to Buy) | |
| Talphera Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2025 | 4,267 | 8,547 (0%) | 0% | 0 | Common Stock | |
| Cue Biopharma Inc | Broadfoot Jill M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 48,800 | 48,800 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 3,750 | 33,017 (0%) | 0% | - | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 3,750 | 3,750 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 03 Feb 2025 | 1,254 | 31,763 (0%) | 0% | 3.8 | 4,740 | Common Stock |
| Talphera Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Talphera Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,280 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 31 May 2024 | 5,000 | 27,960 (0%) | 0% | 1.8 | 8,950 | Common Stock |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 3,750 | 7,500 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill Broadfoot M. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 3,750 | 22,411 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Broadfoot M. Jill | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.69 per share. | 05 Feb 2024 | 1,590 | 20,821 (0%) | 0% | 1.7 | 2,687 | Common stock |
| Atyr Pharma Inc | M. Jill Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Acelrx Pharma Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 3,487 | 3,487 | - | - | Stock Option (Right to Buy) | |
| Acelrx Pharma Inc | Broadfoot Jill M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 581 | 2,106 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 84,023 | 84,023 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 3,750 | 11,250 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 3,750 | 17,026 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.36 per share. | 03 Feb 2023 | 1,566 | 15,460 (0%) | 0% | 2.4 | 3,696 | Common stock |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 75,347 | 75,347 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 13 Jan 2022 | 1,923 | 12,112 (0%) | 0% | 6.7 | 12,980 | Common stock |
| Acelrx Pharma Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Receive) | |
| Acelrx Pharma Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2021 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 54,000 | 54,000 | - | - | Employee Stock Option (Right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2021 | 892 | 0 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2021 | 892 | 10,223 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.66 per share. | 06 Feb 2021 | 390 | 9,833 (0%) | 0% | 7.7 | 2,987 | Common stock |